Potent and selective inhibitor of GABA uptake by GAT-1 (IC50 values are 0.04, 171, 1700 and 622 μM for hGAT-1, rGAT-2, hGAT-3 and hBGT-1 respectively). Anticonvulsant following systemic administration in vivo. Also exhibits cognition-enhancing activity.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 386.88. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.58 mL||12.92 mL||25.85 mL|
|5 mM||0.52 mL||2.58 mL||5.17 mL|
|10 mM||0.26 mL||1.29 mL||2.58 mL|
|50 mM||0.05 mL||0.26 mL||0.52 mL|
References are publications that support the biological activity of the product.
Borden et al (1994) Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur.J.Pharmacol. 269 219 PMID: 7851497
Suzdak et al (1992) NNC-711, a novel potent and selective γ-aminobutyric acid uptake inhibitor: pharmacological characterization. Eur.J.Pharmacol. 224 189 PMID: 1468507
O'Connell et al (2001) Anti-ischemic and cognition-enhancing properties of NNC-711, a γ-aminobutyric acid reuptake inhibitor. Eur.J.Pharmacol. 424 37 PMID: 11470258
If you know of a relevant reference for NNC 711, please let us know.
View Related Products by Product Action
Keywords: NNC 711, NNC 711 supplier, Selective, inhibitors, inhibits, GAT-1, GABA, Transporters, Monoamine, Neurotransmitter, NNC711, 1779, Tocris Bioscience
4 Citations for NNC 711
Citations are publications that use Tocris products. Selected citations for NNC 711 include:
Samoudi et al (2012) Noisy galvanic vestibular stimulation promotes GABA release in the substantia nigra and improves locomotion in hemiparkinsonian rats. PLoS One 7 e29308 PMID: 22238601
Héja et al (2009) Glutamate uptake triggers transporter-mediated GABA release from astrocytes. J Physiol 4 e7153 PMID: 19777062
Kersanté et al (2013) A functional role for both -aminobutyric acid (GABA) transporter-1 and GABA transporter-3 in the modulation of extracellular GABA and GABAergic tonic conductances in the rat hippocampus. Anesthesiology 591 2429 PMID: 23381899
Yoshizumi et al (2012) Gabapentin inhibits γ-amino butyric acid release in the locus coeruleus but not in the spinal dorsal horn after peripheral nerve injury in rats. Pain 116 1347 PMID: 22487864
Do you know of a great paper that uses NNC 711 from Tocris? Please let us know.
Reviews for NNC 711
There are currently no reviews for this product. Be the first to review NNC 711 and earn rewards!
Have you used NNC 711?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.